相关实验视频

Updated: Jun 17, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

在固体瘤中MET变化检测平台和临床影响:全面的文献综述

Pei Yuan¹, Xuemin Xue¹, Tian Qiu¹

¹Department of Pathology, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Therapeutic advances in medical oncology

|January 22, 2024

概括

转基因变异是癌症和EGFR抑制剂等疗法耐药性的关键驱动因素. 本综述涵盖了检测MET外显子14跳转,放大,过度表达和融合,这对于生物标志物引导的癌症治疗至关重要.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

转基因突变变化 (表因子14跳转,放大,过度表达,融合) 在癌症的发展和对向疗法,特别是EGFR抑制剂的耐药性方面至关重要.
这些MET变化在众多固体瘤中作为重要的诊断,预后和预测生物标志物.
检测MET变化是复杂的,因为它们的异质性和各种可用的平台技术.

研究的目的:

审查各种癌症中MET变化的致癌作用.
讨论MET变化的涉及到针对性疗法获得的耐药性.
为选择跨平台技术提供概述和建议,以检测各种MET变化.

主要方法:

综合文献综述,重点关注MET变化和检测方法.
对不同的平台技术进行分析,以识别MET exon 14跳转变体,放大,过度表达和融合.
讨论与当前检测平台相关的挑战和局限性.

主要成果:

证实MET变化是治疗耐药性的显著瘤驱动因素和机制.
为了检测不同类型的MET变异,存在各种分子平台,每个都有特定的敏感性和特异性.
检测中的挑战包括测试复杂性,标准化和跨平台的解释.

结论:

准确而敏感地检测MET变化对于有效的生物标志物导向癌症疗法至关重要.
选择合适的检测平台需要仔细考虑具体的MET变化和临床背景.
检测技术的进一步进步是必要的,以克服目前的局限性,并改善患者的结果.

关键词:

改变MET的变化在MET中放大放大.在MET中,融合是MET.在MET中,过度表达过度.检测平台的检测平台.埃克森14跳过跳过的情况有针对性的治疗方法.

更多相关视频

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...